REG - GSK PLC - Director/PDMR Shareholding
11/02/2026 15:30
For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260211:nRSK6419Sa&default-theme=true
RNS Number : 6419S GSK PLC 11 February 2026
GSK plc (the 'Company')
Vesting of Deferred Annual Bonus Plan Deferred Bonus Awards and Sale of
Ordinary Shares and American Depositary Shares
This notification sets out the vesting details for Persons Discharging
Managerial Responsibilities ('PDMRs') of Deferred Bonus Awards over Ordinary
Shares and American Depositary Shares ('ADS') made in 2023 under the
GlaxoSmithKline 2017 Deferred Annual Bonus Plan ('DABP') and subsequent sale
of Ordinary Shares and ADS to meet tax liabilities. In accordance with the
shareholder approved 2022 Remuneration Policy and the DABP rules, the awards
comprised a mandatory bonus deferral only. The three-year restricted period
for the awards commenced on 9 February 2023 and ended on 8 February 2026. The
awards vested on 9 February 2026. Dividends accrued on the awards during the
restricted period.
The awards were granted in 2023 as restricted awards over ADS for US
participants and as nil-cost options over Ordinary Shares for all other
participants.
The closing prices of Ordinary Shares and of ADS of GSK plc on 9 February 2026
were £21.59 and $59.01.
Transaction notification
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Luke Miels
b) Position/status Chief Executive Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The vesting of an award in the form of a nil-cost option over Ordinary Shares
granted in 2023 under the Company's 2017 Deferred Annual Bonus Plan and the
subsequent exercise of the nil-cost option
c) Price(s) and volume(s) Price(s) Volume(s)
£0.00 60,334
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2026-02-09
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Luke Miels
b) Position/status Chief Executive Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities on the exercise of a
nil-cost option award granted in 2023 under the Company's 2017 Deferred Annual
Bonus Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£22.1140 4,549
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2026-02-09
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Diana Conrad
b) Position/status Chief People Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The vesting of an award in the form of a nil-cost option over Ordinary Shares
granted in 2023 under the Company's 2017 Deferred Annual Bonus Plan and the
subsequent exercise of the nil-cost option
c) Price(s) and volume(s) Price(s) Volume(s)
£0.00 25,742
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2026-02-09
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Diana Conrad
b) Position/status Chief People Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities on the exercise of a
nil-cost option award granted in 2023 under the Company's 2017 Deferred Annual
Bonus Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£22.0162 13,801
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2026-02-09
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name James Ford
b) Position/status SVP and Group General Counsel, Legal and Compliance
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The vesting of an award in the form of a nil-cost option over Ordinary Shares
granted in 2023 under the Company's 2017 Deferred Annual Bonus Plan and the
subsequent exercise of the nil-cost option
c) Price(s) and volume(s) Price(s) Volume(s)
£0.00 25,045
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2026-02-09
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name James Ford
b) Position/status SVP and Group General Counsel, Legal and Compliance
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities on the exercise of a
nil-cost option award granted in 2023 under the Company's 2017 Deferred Annual
Bonus Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£22.0057 11,789
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2026-02-09
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Shobie Ramakrishnan
b) Position/status Chief Digital and Technology Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument American Depositary Shares ('ADS')
ISIN: US37733W2044
b) Nature of the transaction The vesting of an award granted in 2023 under the Company's 2017 Deferred
Annual Bonus Plan
c) Price(s) and volume(s) Price(s) Volume(s)
$0.00 12,522
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2026-02-09
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Shobie Ramakrishnan
b) Position/status Chief Digital and Technology Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument American Depositary Shares ('ADS')
ISIN: US37733W2044
b) Nature of the transaction The sale of ADS to meet tax liabilities on the vesting of an award granted in
2023 under the Company's 2017 Deferred Annual Bonus Plan
c) Price(s) and volume(s) Price(s) Volume(s)
$59.0729 6,497
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2026-02-09
f) Place of the transaction New York Stock Exchange (XNYS)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name David Redfern
b) Position/status President, Corporate Development
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The vesting of an award in the form of a nil-cost option over Ordinary Shares
granted in 2023 under the Company's 2017 Deferred Annual Bonus Plan and the
subsequent exercise of the nil-cost option
c) Price(s) and volume(s) Price(s) Volume(s)
£0.00 34,873
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2026-02-09
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name David Redfern
b) Position/status President, Corporate Development
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities on the exercise of a
nil-cost option award granted in 2023 under the Company's 2017 Deferred Annual
Bonus Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£22.0998 16,415
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2026-02-09
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Regis Simard
b) Position/status President, Global Supply Chain
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The vesting of an award in the form of a nil-cost option over Ordinary Shares
granted in 2023 under the Company's 2017 Deferred Annual Bonus Plan and the
subsequent exercise of the nil-cost option
c) Price(s) and volume(s) Price(s) Volume(s)
£0.00 28,010
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2026-02-09
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Regis Simard
b) Position/status President, Global Supply Chain
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities on the exercise of a
nil-cost option award granted in 2023 under the Company's 2017 Deferred Annual
Bonus Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£22.0451 13,185
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2026-02-09
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Phil Thomson
b) Position/status President, Global Affairs
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The vesting of an award in the form of a nil-cost option over Ordinary Shares
granted in 2023 under the Company's 2017 Deferred Annual Bonus Plan and the
subsequent exercise of the nil-cost option
c) Price(s) and volume(s) Price(s) Volume(s)
£0.00 18,321
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2026-02-09
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Phil Thomson
b) Position/status President, Global Affairs
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities on the exercise of a
nil-cost option award granted in 2023 under the Company's 2017 Deferred Annual
Bonus Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£22.0117 8,633
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2026-02-09
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Deborah Waterhouse
b) Position/status CEO, ViiV Healthcare and President, Global Health, GSK
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The vesting of an award in the form of a nil-cost option over Ordinary Shares
granted in 2023 under the Company's 2017 Deferred Annual Bonus Plan and the
subsequent exercise of the nil-cost option
c) Price(s) and volume(s) Price(s) Volume(s)
£0.00 44,631
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2026-02-09
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Deborah Waterhouse
b) Position/status CEO, ViiV Healthcare and President, Global Health, GSK
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities on the exercise of a
nil-cost option award granted in 2023 under the Company's 2017 Deferred Annual
Bonus Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£22.0267 21,009
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2026-02-09
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Tony Wood
b) Position/status Chief Scientific Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The vesting of an award in the form of a nil-cost option over Ordinary Shares
granted in 2023 under the Company's 2017 Deferred Annual Bonus Plan and the
subsequent exercise of the nil-cost option
c) Price(s) and volume(s) Price(s) Volume(s)
£0.00 21,176
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2026-02-09
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Tony Wood
b) Position/status Chief Scientific Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities on the exercise of a
nil-cost option award granted in 2023 under the Company's 2017 Deferred Annual
Bonus Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£22.1186 9,978
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2026-02-09
f) Place of the transaction London Stock Exchange (XLON)
About GSK
GSK is a global biopharma company with a purpose to unite science, technology,
and talent to get ahead of disease together. Find out more at www.gsk.com
(http://www.gsk.com/) .
Registered in England & Wales:
No. 3888792
Registered Office:
79 New Oxford Street
London
WC1A 1DG
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END DSHSFUFLFEMSESE
Copyright 2019 Regulatory News Service, all rights reservedRecent news on GSK
See all newsREG - GSK PLC - Director/PDMR Shareholding
AnnouncementREG - GSK PLC - Transaction in Own Shares
AnnouncementREG - GSK PLC - Linerixibat accepted for priority review in China
AnnouncementREG - GSK PLC - Transaction in Own Shares
AnnouncementREG - GSK PLC - Bepirovirsen accepted for Japan regulatory review
Announcement